Extrapyramidal side effects with low doses of amisulpride
نویسندگان
چکیده
منابع مشابه
Extrapyramidal Side Effects with Low Dose Amisulpride: A Report of Two Cases
Amisulpride, recently introduced atypical antipsychotic, is well-known for its broad spectrum effectiveness and lower profile for extrapyramidal side effects (EPS). Its selective affinity for dopamine receptors in the limbic structures, but not in the striatum, leads to a low risk of extrapyramidal side effects. Here, we report two cases of EPS associated with lower dose of amisulpride. The pro...
متن کاملExtrapyramidal side-effects of antipsychotics in a randomised trial.
BACKGROUND There are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs. AIMS To compare the incidence of treatment-emergent EPS between second-generation antipsychotics and perphenazine in people with schizophrenia. METHOD Incidence analyses integrated data from standardised rating scales and documented use of c...
متن کاملNeuronal basis of neuroleptic-induced extrapyramidal side effects.
The article reviews presently commonly accepted concepts of neuronal basis of neuroleptic-induced extrapyramidal side effects. The data obtained both, in humans and laboratory animals, point to the blockade of a large number of the striatal dopamine D2 receptors by neuroleptics as a primary cause of these disturbances. This phenomenon leads to the appearance of parkinsonian symptoms shortly aft...
متن کاملLow-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: An effect size analysis.
A meta-analysis of the published literature was performed in order to quantify the efficacy of low-dose neuroleptic therapy in reducing extrapyramidal side effects in schizophrenic patients. A low-dose regimen between 50-100 mg equivalents of chlorpromazine, in comparison to a standard-dose regimen between 200-500 mg reduced extrapyramidal side effects by a 0.30 (+/-0.12) standard deviation, wh...
متن کاملExtrapyramidal side-effects and antipsychotics: are second-generation agents
Peluso et al report on the differential effect of first-generation antipsychotics (FGAs) v. second-generation antipsychotics (SGAs) in ameliorating or exacerbating extrapyramidal side-effects (EPS) in a secondary analysis of the CUtLASS-1 trial data. They report their findings as ‘essentially null’ and mention that there is weak evidence for clinically significant differences in emergent or rel...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Psychiatry
سال: 2014
ISSN: 0019-5545
DOI: 10.4103/0019-5545.130510